Country comparison
CAR-T in China vs the United States
7 min read · Last verified: 2026-09-09
How CAR-T access works in the United States
The US has the deepest CAR-T infrastructure in the world. Since the first FDA approval in 2017, the agency has approved a growing list of products covering CD19 and BCMA targets — for B-cell lymphomas, acute lymphoblastic leukemia, mantle cell lymphoma, and multiple myeloma. Treatment happens at accredited centers, and most major metro areas have at least one.
The price is the problem. List prices run $373,000–475,000 for the product alone, before hospital care, and the total billed rises further if complications need ICU-level management. What a patient actually pays depends on insurance:
- Medicare has covered FDA-approved CAR-T since 2019.
- Private insurance generally covers approved indications, with prior authorization and plan-specific out-of-pocket maximums.
- Uninsured or underinsured patients face the list price itself — which is where comparisons with China begin.
When US patients look at China
Honest triggers, in rough order of frequency:
- No workable coverage. A denied claim, an off-label use the insurer will not fund, or no insurance at all. A self-pay US journey can exceed the drug list price once hospital costs land.
- Cost even with insurance. High-deductible plans can leave five-figure out-of-pocket exposure; some patients compare that against a fully priced alternative abroad.
- A specific product or target. China’s NMPA has approved six CAR-T products covering CD19 and BCMA; not every product or indication available there has a US counterpart at the same line of therapy.
- Manufacturing or center slots. At some US centers the wait for a manufacturing slot can stretch — sometimes longer than the disease allows.
The documented numbers: a complete commercial journey in China typically totals $170,000–260,000, with product list prices of $140,000–180,000 (site dataset, NMPA list prices, verified 2026-07). That is roughly one-third of the US drug list price alone. See the itemized cost page.
The honest trade-offs
If you have coverage and access to an accredited US center, staying home is usually the better option. Your out-of-pocket cost is capped, your own team manages the highest-risk weeks after infusion, and follow-up is local by default. China rarely beats that equation.
Travel changes the risk picture. A China journey means six to ten weeks abroad, with the highest-risk window in the first days after infusion and a long flight home not long after the monitoring period ends. And follow-up is a handoff, not a continuation: your US oncologist must accept a bilingual discharge package and a monitoring plan written by a team they have never worked with. Raise that with them before you book anything, not after.
Be honest about what the lower price reflects: a different product, a different health system, and a team you leave behind when you fly home. None of that makes it a bad choice — for an uninsured patient it can be the only realistic one — but it is not the same treatment wrapped in a cheaper invoice.
Questions to ask your treating team
- Does my diagnosis match an FDA-approved indication, and will my insurer confirm coverage in writing — including my out-of-pocket maximum?
- If coverage is denied, what is the appeals path, and what would self-pay actually total at a US center?
- Is there a US clinical trial for my situation?
- If I were treated abroad, would you take over my monitoring — and what records would you need from the treating hospital?
Where to go next
Compare with another country